NewGenIvf Group Limited (Nasdaq: NIVF), a technology-driven diversified growth company, provided a comprehensive business update on November 16, 2026, detailing progress across its core sectors: reproductive health, digital assets, and real estate development.
In July 2025, NewGen acquired advanced cytometry intellectual property and equipment, marking a significant expansion in its technology portfolio. To facilitate regulatory approval, the company engaged Shenzhen Siyu Enterprise Management Consulting Co., Ltd., a specialist in China medical device registration, to manage the registration of its NX One microfluidic platform with China’s National Medical Products Administration (NMPA). The consultancy covers classification strategy, type-testing coordination, dossier preparation, and regulatory communications.
Nodexus Limited, NewGen’s wholly-owned Hong Kong subsidiary and developer of the NX One platform, entered a non-binding collaboration agreement with Hainan Provincial Cancer Hospital. This agreement outlines the parties’ intent to collaborate on scientific validation, clinical research, and eventual clinical translation of the NX One device for tumor precision diagnosis, treatment, and cell research. The collaboration aims to generate real-world data supporting future clinical validation and application in China. However, the agreement remains non-binding with no guarantee of a definitive contract.
On the digital assets front, NewGen completed the acquisition of a 2% equity stake in PredicXion Group Limited, operator of K25.ai, and agreed to acquire an additional 11% equity interest. On November 10, 2026, K25 Group announced the imminent launch of K25.fun, a membership platform offering exclusive concert experiences, limited-edition collectibles, and fan quests targeting K-pop audiences across the Asia-Pacific region. This initiative exemplifies K25’s strategy to convert audience engagement into new consumer revenue streams.
In real estate, NewGen has paid deposits totaling US$4.71 million toward acquiring land for a development project in Ras Al Khaimah, United Arab Emirates. As of the update, a definitive sale and purchase agreement for the land has not been finalized.
Regarding its legacy business, NewGen reported that revenue from its IVF and assisted reproductive treatment services remained broadly flat for the six months ended June 30, 2026, compared to the same period in 2025. Management attributed this stability to an industry-wide decline in fertility service demand and the impact of the Thailand-Cambodia conflict on patient travel.
Financially, as of June 30, 2026, NewGen’s unaudited condensed consolidated financial statements revealed total assets of approximately US$36.4 million, inclusive of the US$4.71 million land acquisition deposits. Equity attributable to shareholders stood at approximately US$26.4 million, with total shareholders’ equity, including non-controlling interests, at about US$25.7 million. The increase in total assets compared to June 30, 2025, primarily reflects the acquisition of cytometry intellectual property and investment in K25.ai.
NewGen operates through three main divisions: NewGenProperty, focusing on real estate projects in Ras Al Khaimah; NewGenDigital, dedicated to digital asset and decentralized finance solutions; and NewGenSup, which concentrates on health and longevity products. The company’s foundational IVF and assisted reproductive treatment services continue across Asia.
The company’s forward-looking statements address plans to seek regulatory registration of NX One with both the NMPA and the U.S. Food and Drug Administration, potential listing of Nodexus Limited on the Hong Kong Stock Exchange, completion of investments in K25.ai, and the finalization of its real estate acquisition. These statements also acknowledge risks including regulatory delays, potential non-completion of agreements, geopolitical tensions, and market demand fluctuations.
NewGen cautions that actual results may differ materially due to these risks and uncertainties, as detailed in its filings with the U.S. Securities and Exchange Commission. The company does not undertake any obligation to update forward-looking statements except as required by law.
NewGenIvf Group Reports Strategic Advances in Cytometry, Digital Assets, and Real Estate Ventures NewGenIvf Group Limited (Nasdaq: NIVF) disclosed key developments across its diversified business segments, including regulatory filings for its NX One microfluidic platform in China, a collaboration agreement with Hain... Read the full IIPLA article: https://iipla.org/news/newgenivf-group-reports-strategic-advances-in-cytometry-digital-assets-and-real-estate-ventures